US6103224A
(en)
*
|
1985-02-05 |
2000-08-15 |
Chiron Corporation |
N∇2 CSF-1 (short form) and carboxy truncated fragments thereof
|
US5422105A
(en)
*
|
1985-02-05 |
1995-06-06 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor 1
|
US5837229A
(en)
*
|
1985-02-05 |
1998-11-17 |
Chiron Corporation |
Uses of recombinant colony stimulating factor-1
|
US6156300A
(en)
*
|
1985-02-05 |
2000-12-05 |
Chiron Corporation |
Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
|
US5556620A
(en)
*
|
1985-02-05 |
1996-09-17 |
Cetus Oncology Corporation |
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
US5104650A
(en)
*
|
1985-02-05 |
1992-04-14 |
Cetus Corporation |
Uses of recombinant colony stimulating factor-1
|
US5573930A
(en)
*
|
1985-02-05 |
1996-11-12 |
Cetus Oncology Corporation |
DNA encoding various forms of colony stimulating factor-1
|
US5650297A
(en)
*
|
1986-09-17 |
1997-07-22 |
Otsuka Pharmaceutical Co., Ltd. |
DNA encoding human colony-stimulating factors
|
US5084559A
(en)
*
|
1987-03-27 |
1992-01-28 |
Repligen Corporation |
Protein a domain mutants
|
US5153265A
(en)
*
|
1988-01-20 |
1992-10-06 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
JPH01193227A
(ja)
*
|
1988-01-29 |
1989-08-03 |
Res Dev Corp Of Japan |
癌免疫療法補助剤
|
US5322678A
(en)
*
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
US5349052A
(en)
*
|
1988-10-20 |
1994-09-20 |
Royal Free Hospital School Of Medicine |
Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
|
GB8824591D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
US5264214A
(en)
*
|
1988-11-21 |
1993-11-23 |
Collagen Corporation |
Composition for bone repair
|
CA2006596C
(fr)
*
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
G-csf modifie chimiquement
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US6225449B1
(en)
*
|
1991-10-04 |
2001-05-01 |
Washington University |
Hormone analogs with multiple CTP extensions
|
US5288487A
(en)
*
|
1989-02-28 |
1994-02-22 |
Morinaga Milk Industry Co., Ltd. |
Human monocyte-macrophage-CSF preparations
|
DE69034200T2
(de)
*
|
1989-04-19 |
2006-05-24 |
Enzon, Inc. |
Verfahren zum Herstellen von modifizierten Polypeptiden die eine Polypeptid und ein Polyalkylenoxid enthalten
|
US7264944B1
(en)
*
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
IL95031A
(en)
*
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US6248319B1
(en)
|
1989-10-16 |
2001-06-19 |
Krisztina M. Zsebo |
Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
|
US6204363B1
(en)
|
1989-10-16 |
2001-03-20 |
Amgen Inc. |
Stem cell factor
|
US7144731B2
(en)
*
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
GEP20002145B
(en)
*
|
1989-10-16 |
2000-06-25 |
Amgen Inc Us |
Stem Cell Factor
|
US6207454B1
(en)
|
1989-10-16 |
2001-03-27 |
Amgen Inc. |
Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
|
DE69033584T2
(de)
|
1989-10-16 |
2001-03-08 |
Amgen Inc., Thousand Oaks |
Stammzellenfaktor
|
EP0452505A4
(en)
*
|
1989-11-07 |
1991-10-30 |
Otsuka Pharmaceutical Co., Ltd. |
M-csf derivative, expression vector of said derivative, product of transformation by said vector, and production of them
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5951972A
(en)
*
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
ES2113354T3
(es)
*
|
1990-05-04 |
1998-05-01 |
American Cyanamid Co |
Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
JP3051145B2
(ja)
*
|
1990-08-28 |
2000-06-12 |
住友製薬株式会社 |
新規なポリエチレングリコール誘導体修飾ペプチド
|
US5219991A
(en)
*
|
1990-09-21 |
1993-06-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Macrophage stimulating protein
|
WO1992016221A1
(fr)
*
|
1991-03-15 |
1992-10-01 |
Synergen, Inc. |
Pegylation de polypeptides
|
WO1992016555A1
(fr)
*
|
1991-03-18 |
1992-10-01 |
Enzon, Inc. |
Conjuges de polypeptides et de glycopolypeptides associes a des polymeres, contenant de l'hydrazine
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
NZ244778A
(en)
*
|
1991-10-21 |
1994-03-25 |
Ortho Pharma Corp |
Peg imidates and protein derivatives thereof
|
JPH06506479A
(ja)
*
|
1991-11-25 |
1994-07-21 |
デイド、インターナショナル、インコーポレイテッド |
合成htlv−2ペプチドを用いるイムノアッセイ
|
IT1260468B
(it)
*
|
1992-01-29 |
1996-04-09 |
|
Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
|
FR2687681B1
(fr)
*
|
1992-02-20 |
1995-10-13 |
Transgene Sa |
Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
|
JPH08502082A
(ja)
*
|
1992-07-02 |
1996-03-05 |
コラーゲン コーポレイション |
生体適合性ポリマー結合体
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
WO1994005332A2
(fr)
*
|
1992-09-01 |
1994-03-17 |
Berlex Laboratories, Inc. |
Glycolation de macromolecules glycosylees
|
NZ250375A
(en)
*
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
WO1994020453A1
(fr)
*
|
1993-03-09 |
1994-09-15 |
Enzon, Inc. |
Conjugues d'oxyde de polyalkylene de taxol, et intermediaires de taxol
|
WO1994028024A1
(fr)
*
|
1993-06-01 |
1994-12-08 |
Enzon, Inc. |
Polymere modifie aux glucides presentant une activite erythropoïetique
|
IL110787A0
(en)
*
|
1993-08-27 |
1994-11-11 |
Sandoz Ag |
Biodegradable polymer, its preparation and pharmaceutical composition containing it
|
CA2174350A1
(fr)
*
|
1993-10-20 |
1995-04-27 |
Richard B. Greenwald |
Substances taxoides substituees en position 2' et/ou 7'
|
US8241900B1
(en)
|
1994-01-03 |
2012-08-14 |
Genentech, Inc. |
mpl ligand
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
US8147844B1
(en)
|
1994-01-03 |
2012-04-03 |
Genentech, Inc. |
Mpl ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using mpl ligand
|
DE4404168A1
(de)
*
|
1994-02-10 |
1995-08-17 |
Hoechst Ag |
Hirudinderivate und Verfahren zu deren Herstellung
|
US8278099B1
(en)
|
1994-02-15 |
2012-10-02 |
Genentech, Inc. |
Monoclonal antibody to human thrombopoietin
|
DK0690127T3
(da)
*
|
1994-03-31 |
1999-05-03 |
Amgen Inc |
Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US6833408B2
(en)
*
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
US7883693B2
(en)
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
JP4193917B2
(ja)
*
|
1995-12-18 |
2008-12-10 |
アンジオデバイス インターナショナル ゲーエムベーハー |
架橋ポリマー組成物およびその使用方法
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US6072040A
(en)
*
|
1996-10-15 |
2000-06-06 |
Medical Analysis Systems, Inc. |
Stabilized conjugates of uncomplexed subunits of multimeric proteins
|
DK0942740T3
(da)
|
1996-12-06 |
2003-12-15 |
Amgen Inc |
Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
|
US7285267B2
(en)
|
1997-01-14 |
2007-10-23 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptors 6α & 6β
|
US20040013664A1
(en)
*
|
1997-01-14 |
2004-01-22 |
Gentz Reiner L. |
Tumor necrosis factor receptors 6 alpha & 6 beta
|
CN1247567A
(zh)
*
|
1997-01-14 |
2000-03-15 |
人体基因组科学有限公司 |
肿瘤坏死因子受体6α和6β
|
US5965704A
(en)
*
|
1997-08-05 |
1999-10-12 |
Zymogenetics, Inc. |
Class two cytokine receptor-11
|
US6391311B1
(en)
*
|
1998-03-17 |
2002-05-21 |
Genentech, Inc. |
Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
|
US6458355B1
(en)
*
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
*
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US7371836B2
(en)
*
|
1998-03-27 |
2008-05-13 |
Genentech, Inc. |
PRO526 nucleic acids
|
CN1896231B
(zh)
*
|
1998-08-06 |
2012-09-05 |
山景药品公司 |
分离四聚体尿酸氧化酶的方法
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
KR100841634B1
(ko)
|
1998-08-06 |
2008-06-26 |
듀크 유니버시티 |
요산염 산화효소
|
US20060188971A1
(en)
*
|
1998-08-06 |
2006-08-24 |
Duke University |
Urate oxidase
|
EP1109568A4
(fr)
*
|
1998-09-04 |
2002-05-08 |
Ludwig Inst Cancer Res |
Peptide antigenique code par un autre cadre de lecture ouvert de facteur stimulant la proliferation des macrophages
|
CN100480266C
(zh)
*
|
1998-10-16 |
2009-04-22 |
拜奥根Idec马萨诸塞公司 |
干扰素-β融合蛋白及用途
|
LT2599503T
(lt)
*
|
1998-10-16 |
2017-06-26 |
Biogen Ma Inc. |
Interferono beta-1a polimero konjugatai ir jų panaudojimas
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000028035A1
(fr)
*
|
1998-11-10 |
2000-05-18 |
Human Genome Sciences Inc. |
CHEMOKINE β-7
|
EA004685B1
(ru)
*
|
1999-01-29 |
2004-06-24 |
Эмджен Инк. |
Конъюгаты гксф
|
JP4670150B2
(ja)
*
|
1999-04-02 |
2011-04-13 |
味の素株式会社 |
多量体蛋白質に由来するサブユニットペプチドの製造法
|
US20050079577A1
(en)
*
|
1999-05-14 |
2005-04-14 |
Ashkenazi Avi J. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
JP2003519478A
(ja)
|
2000-01-10 |
2003-06-24 |
マキシゲン・ホールディングズ・リミテッド |
G−csf結合体
|
DE60138364D1
(de)
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
AR032757A1
(es)
*
|
2000-06-30 |
2003-11-26 |
Smithkline Beecham Corp |
Composiciones biologicamente activas de conjugados de quimioquina, uso de dichas composiciones en la fabricacion de composiciones farmaceuticas, metodo para preparar dichas composiciones, y metodos para mejorar la farmacocinetica de una quimioquina
|
JP5015404B2
(ja)
*
|
2000-08-08 |
2012-08-29 |
ザイモジェネティクス, インコーポレイテッド |
可溶性zcytor11サイトカイン受容体
|
ATE320007T1
(de)
*
|
2000-10-23 |
2006-03-15 |
Inst Genetics Llc |
Säureempfindliches isotop-codiertes extrahiermittel (alice) in massenspectrometrieanalyse
|
EP1353622A4
(fr)
*
|
2000-11-03 |
2005-06-22 |
Smithkline Beecham Corp |
Procede pour ameliorer l'exposition systemique de proteines therapeutiques administrees par voie sous-cutanee
|
MXPA03007619A
(es)
|
2001-02-27 |
2003-12-04 |
Maxygen Aps |
Nuevas moleculas similares a interferon beta.
|
DE10112825A1
(de)
*
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
MXPA03010575A
(es)
*
|
2001-05-16 |
2005-03-07 |
Yeda Res & Dev |
Uso de inhibidores de il-08 para el tratamiento o prevencion de sepsis.
|
US20020198139A1
(en)
*
|
2001-05-17 |
2002-12-26 |
Deutschman Clifford S. |
Method of preventing acute pulmonary cell injury
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7157277B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
SG159381A1
(en)
*
|
2001-10-10 |
2010-03-30 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7173003B2
(en)
*
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
DE10209821A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
DE10209822A1
(de)
*
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
CN1655812A
(zh)
*
|
2002-03-26 |
2005-08-17 |
拜奥辛尼克休斯公司 |
抗微生物聚合物轭合物
|
AU2003237789A1
(en)
*
|
2002-03-26 |
2003-10-13 |
Biosynexus, Incorporated |
Enzyme disruption of bacterial biofilms
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
WO2004000366A1
(fr)
|
2002-06-21 |
2003-12-31 |
Novo Nordisk Health Care Ag |
Glycoformes du facteur vii pegylees
|
EP1549332A4
(fr)
*
|
2002-09-05 |
2008-06-18 |
Gen Hospital Corp |
Asialo-interferons modifies et utilisations correspondantes
|
DE10242076A1
(de)
*
|
2002-09-11 |
2004-03-25 |
Fresenius Kabi Deutschland Gmbh |
HAS-Allergen-Konjugate
|
EP1681303B1
(fr)
*
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
Polypeptides HASylés, en particulier érythropoiétine HASylée
|
ES2214166T1
(es)
*
|
2002-09-11 |
2004-09-16 |
Fresenius Kabi Deutschland Gmbh |
Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
|
CA2496317C
(fr)
*
|
2002-09-11 |
2014-02-18 |
Fresenius Kabi Deutschland Gmbh |
Procede de production de derives d'amidon hydroxyalkyle
|
AU2003272585B2
(en)
*
|
2002-09-20 |
2009-12-10 |
Pharmacia Corporation |
Process for decreasing aggregate levels of pegylated protein
|
AU2003273413A1
(en)
*
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
JP2004196770A
(ja)
*
|
2002-10-24 |
2004-07-15 |
Effector Cell Institute Inc |
樹状細胞前駆体の血中レベル上昇剤
|
EA008866B1
(ru)
|
2002-12-26 |
2007-08-31 |
Маунтин Вью Фамэсьютикэлс, Инк. |
ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
|
KR101162908B1
(ko)
*
|
2002-12-26 |
2012-07-06 |
마운틴 뷰 파마슈티컬즈, 인크. |
수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
|
EP1594459B1
(fr)
|
2002-12-30 |
2010-02-17 |
Angiotech International Ag |
Liberation de medicaments a partir d'une composition polymere a gelification rapide
|
JP2006519766A
(ja)
*
|
2002-12-30 |
2006-08-31 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
組織反応性化合物および組成物、ならびにそれらの使用法
|
CA2519092C
(fr)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Polymeres hydrosolubles ramifies et conjugues de ceux-ci
|
ATE475673T1
(de)
*
|
2003-03-24 |
2010-08-15 |
Zymogenetics Inc |
Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
|
US20100221237A1
(en)
*
|
2003-03-26 |
2010-09-02 |
Biosynexus Incorporated |
Enzyme disruption of bacterial biofilms
|
EP1615945B1
(fr)
*
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
WO2006127896A2
(fr)
*
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Facteur ix glycopegyle
|
EP1613274B1
(fr)
|
2003-04-15 |
2010-03-03 |
GlaxoSmithKline LLC |
Mutants par substitution de l'interleukine 18 humaine et ces conjugues
|
ATE540055T1
(de)
*
|
2003-05-09 |
2012-01-15 |
Biogenerix Ag |
Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005014024A2
(fr)
*
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugues de polymere et de proteine lies au moyen d'un groupe de liaison oxime
|
US20080274948A1
(en)
*
|
2003-08-08 |
2008-11-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of Hydroxyalkyl Starch and G-Csf
|
WO2005014655A2
(fr)
*
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugues d'amidon d'hydroxyalkyle et de proteine
|
EP2263684A1
(fr)
|
2003-10-10 |
2010-12-22 |
Novo Nordisk A/S |
Dérives de IL-21
|
EP2641611A3
(fr)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Thérapie combinée
|
US20050208095A1
(en)
*
|
2003-11-20 |
2005-09-22 |
Angiotech International Ag |
Polymer compositions and methods for their use
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
CN101072789B
(zh)
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
NZ548256A
(en)
|
2004-02-02 |
2010-02-26 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
EP2336192A1
(fr)
*
|
2004-03-11 |
2011-06-22 |
Fresenius Kabi Deutschland GmbH |
Conjugues d'amidon hydroxyalkyle et d'une protein, preparer par amination réductive
|
AR048918A1
(es)
*
|
2004-03-11 |
2006-06-14 |
Fresenius Kabi De Gmbh |
Conjugados de almidon de hidroxietilo y eritropoyetina
|
WO2006083260A2
(fr)
|
2004-04-28 |
2006-08-10 |
Angiotech Biomaterials Corporation |
Compositions et systemes pour la formation de biomateriaux reticules et procedes associes de preparation et d'utilisation
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
US20090292110A1
(en)
*
|
2004-07-23 |
2009-11-26 |
Defrees Shawn |
Enzymatic modification of glycopeptides
|
WO2006031811A2
(fr)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Interferon alpha glycopegyle
|
CA2581093C
(fr)
|
2004-09-17 |
2014-11-18 |
Angiotech Biomaterials Corporation |
Composes multifonctionels pour la formation de biomateriaux reticules et leurs procedes de preparation et d'utilisation
|
AU2005299809B2
(en)
*
|
2004-10-22 |
2010-12-02 |
Zymogenetics, Inc. |
Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
CA2584510C
(fr)
*
|
2004-10-25 |
2013-05-28 |
Intezyne Technologies, Incorporated |
Poly(ethyleneglycol) heterobifonctionnel et utilisations associees
|
HUE026826T2
(en)
|
2004-10-29 |
2016-07-28 |
Ratiopharm Gmbh |
Modeling and glycopegylation of fibroblast growth factor (FGF)
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
MX2007007732A
(es)
*
|
2004-12-22 |
2007-10-08 |
Kuros Biosurgery Ag |
Hidrogeles peg con grupos funcionales para la reaccion de adicion tipo michael con biofactores incorporados con el factor xiiia.
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
KR20070099013A
(ko)
*
|
2005-01-31 |
2007-10-08 |
주식회사 에펙타 세포연구소 |
면역 증강제
|
CN101137396A
(zh)
*
|
2005-03-11 |
2008-03-05 |
弗雷泽纽斯卡比德国有限公司 |
由无活性初始材料制备生物活性糖蛋白
|
WO2006121569A2
(fr)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
|
US20080159976A1
(en)
*
|
2005-04-11 |
2008-07-03 |
Jacob Hartman |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
LT3321359T
(lt)
|
2005-04-11 |
2021-05-10 |
Horizon Pharma Rheumatology Llc |
Urato oksidazės variantinės formos ir jų panaudojimas
|
BRPI0612942A2
(pt)
|
2005-04-11 |
2012-10-09 |
Savient Pharmaceuticals Inc |
forma variante de oxidase de urato e uso do mesmo
|
US8148123B2
(en)
*
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
JP2008545665A
(ja)
*
|
2005-05-23 |
2008-12-18 |
ユニベルシテ ドゥ ジュネーブ |
高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
|
EP1888098A2
(fr)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Formulations d'erythropoietine glycopegylees
|
EP1893632B1
(fr)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Reduction et derivation séléctives de proteines facteur vii comprenant au moins une cysteine non native
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US20090305967A1
(en)
*
|
2005-08-19 |
2009-12-10 |
Novo Nordisk A/S |
Glycopegylated factor vii and factor viia
|
EP1762250A1
(fr)
*
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugués d' amidon hydroxyalkyle et une substance active obtenue par ligation chimique via thiazolidine
|
US8168592B2
(en)
*
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
AU2006315347A1
(en)
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
EP2013225B1
(fr)
*
|
2006-04-12 |
2014-12-17 |
Crealta Pharmaceuticals LLC |
Purification de protéines au moyen d'un tensioactif cationique
|
CA2650035C
(fr)
|
2006-04-27 |
2015-02-03 |
Intezyne Technologies, Inc. |
Poly(ethylene glycol) contenant des endogroupes chimiquement disparates
|
BRPI0712008A2
(pt)
|
2006-05-24 |
2012-01-10 |
Novo Nordisk Healthcare Ag |
derivados e análogos de fix prolongados
|
ES2516694T3
(es)
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
BRPI0715072A2
(pt)
*
|
2006-08-03 |
2013-06-25 |
Orico Ltd |
antagonistas de miostatina
|
ITMI20061624A1
(it)
|
2006-08-11 |
2008-02-12 |
Bioker Srl |
Mono-coniugati sito-specifici di g-csf
|
CA2663083A1
(fr)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
WO2008088422A2
(fr)
*
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Agents thérapeutiques à base de peptides toxiques
|
WO2008121563A2
(fr)
|
2007-03-30 |
2008-10-09 |
Ambrx, Inc. |
Polypeptides fgf-21 modifiés, et leurs utilisations
|
PL2144923T3
(pl)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
Sposoby leczenia z użyciem glikopegilowanego G-CSF
|
DK2136850T3
(da)
*
|
2007-04-13 |
2012-04-10 |
Kuros Biosurgery Ag |
Polymervævforsegling
|
CA2687141C
(fr)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions et procedes pour produire des proteines de fusion bioactives
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
US7968811B2
(en)
*
|
2007-06-29 |
2011-06-28 |
Harley-Davidson Motor Company Group, Inc. |
Integrated ignition and key switch
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
EP2070950A1
(fr)
*
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation
|
EP2070951A1
(fr)
*
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Procédé de production d'un dérivé hydroxyalkyle de l'amidon avec deux liens
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
WO2009108806A1
(fr)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Molécules de facteur viii conjuguées
|
EP3225248B1
(fr)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Polypeptides g-csf bovins modifiés et leurs utilisations
|
JP5602738B2
(ja)
*
|
2008-08-25 |
2014-10-08 |
ビロメッド カンパニー, リミテッド |
インターロイキン−11類似体を含む生体ポリマー結合体
|
CA2738033C
(fr)
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Vaccins et micro-organismes dependant de la replication d'acide amine non naturels
|
CA2737026C
(fr)
|
2008-09-26 |
2019-12-24 |
Ambrx, Inc. |
Polypeptides d'erythropoietine animale modifies et leurs utilisations
|
HUP1200205A3
(en)
|
2009-06-25 |
2012-09-28 |
Savient Pharmaceuticals |
Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
|
RU2744370C2
(ru)
|
2009-07-27 |
2021-03-05 |
Баксалта Инкорпорейтед |
Конъюгаты белков свертывания крови
|
CA2769244A1
(fr)
|
2009-07-27 |
2011-02-03 |
Lipoxen Technologies Limited |
Glyco-polysialylation de proteines de coagulation non sanguine
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
EP2542569B1
(fr)
|
2010-03-05 |
2020-09-16 |
Omeros Corporation |
Molécules chimériques inhibitrices d'activation du complément
|
JP2013528374A
(ja)
|
2010-05-10 |
2013-07-11 |
パーシード セラピューティクス リミテッド ライアビリティ カンパニー |
Vla4のポリペプチド阻害剤
|
SI2601214T1
(en)
*
|
2010-08-06 |
2018-03-30 |
Genzyme Corporation |
VEGF antagonist compositions and their use
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
US9340590B2
(en)
|
2011-03-16 |
2016-05-17 |
Amgen Inc. |
Potent and selective inhibitors of NaV1.3 and NaV1.7
|
KR20140054009A
(ko)
|
2011-07-01 |
2014-05-08 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
릴랙신 융합 폴리펩타이드 및 그의 용도
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP2863955B1
(fr)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Protéines de fc modifiées, comprenant des résidus d'acides aminés non naturels spécifiques de site, leurs conjugués, leur préparation et leurs procédés d'utilisation
|
ES2728864T3
(es)
|
2012-08-31 |
2019-10-29 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
WO2014165277A2
(fr)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
Inhibiteurs sélectifs et puissants de nav1.7
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
EP3055298B1
(fr)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
|
JP6803236B2
(ja)
|
2014-06-10 |
2020-12-23 |
アムジェン インコーポレイテッド |
アペリンポリペプチド
|
MX2017004947A
(es)
|
2014-10-24 |
2017-06-29 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
|
KR102670432B1
(ko)
|
2017-02-08 |
2024-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
AU2020223031A1
(en)
|
2019-02-12 |
2021-08-19 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
CN115243726A
(zh)
|
2020-03-11 |
2022-10-25 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
EP4199968A1
(fr)
|
2020-08-20 |
2023-06-28 |
Ambrx, Inc. |
Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
|
MX2023011480A
(es)
|
2021-04-03 |
2023-12-06 |
Ambrx Inc |
Conjugados anticuerpo anti-her2-fármaco y usos de estos.
|